Patents by Inventor Jeff Zhiqiang Lu

Jeff Zhiqiang Lu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Compounds and methods for inhibiting hepatitis C virus replication
    Publication number: 20090215983
    Abstract: The inventors have discovered that an ATPase-deficient dominant-negative mutant NS3 protein of hepatitis C virus inhibits activity of the wild-type NS3 protein and inhibits replication of hepatitis C virus (HCV). The solved crystal structure of a multi-enzyme NS3 complex on a DNA substrate is also provided. The inventors have tested a peptide matching the sequence of a portion of NS3 that interacts with another NS3 molecule for inhibiting HCV replication. The peptide inhibits HCV replication. Accordingly, the invention provides a method of inhibiting HCV replication in cells infected with HCV involving transforming the cells with a vector expressing a dominant-negative mutant NS3 gene. The invention also provides a method of inhibiting HCV replication in cells infected with HCV involving administering to the cells a dominant-negative mutant NS3 protein. The invention also provides peptides and agents that inhibit HCV replication and methods of identifying agents that inhibit HCV replication.
    Type: Application
    Filed: November 10, 2008
    Publication date: August 27, 2009
    Inventors: Kevin D. Raney, Craig E. Cameron, Bhuvanesh Dave, Joshua Sakon, Jeff Zhiqiang Lu, Samuel G. Mackintosh, Thomas A. Jennings
  • Compounds and methods for inhibiting hepatitis C virus replication
    Patent number: 7465537
    Abstract: The inventors have discovered that an ATPase-deficient dominant-negative mutant NS3 protein of hepatitis C virus inhibits activity of the wild-type NS3 protein and inhibits replication of hepatitis C virus (HCV). The solved crystal structure of a multi-enzyme NS3 complex on a DNA substrate is also provided. The inventors have tested a peptide matching the sequence of a portion of NS3 that interacts with another NS3 molecule for inhibiting HCV replication. The peptide inhibits HCV replication. Accordingly, the invention provides a method of inhibiting HCV replication in cells infected with HCV involving transforming the cells with a vector expressing a dominant-negative mutant NS3 gene. The invention also provides a method of inhibiting HCV replication in cells infected with HCV involving administering to the cells a dominant-negative mutant NS3 protein. The invention also provides peptides and agents that inhibit HCV replication and methods of identifying agents that inhibit HCV replication.
    Type: Grant
    Filed: May 1, 2005
    Date of Patent: December 16, 2008
    Assignee: The Board of Trustees of the University of Arkansas
    Inventors: Kevin D. Raney, Craig E. Cameron, Bhuvanesh Dave, Joshua Sakon, Jeff Zhiqiang Lu, Samuel G. Mackintosh, Thomas A. Jennings